Balancing patient autonomy against public-health safeguards is a core ethical dilemma for drug regulators. Discuss.

Patient autonomy is a person's right to make informed choices about their own treatment. Public-health safeguards require a medicine to be shown safe and effective before people take it. The two clashed when the U.S. Health Secretary issued an "enforcement discretion policy". It lets licensed pharmacies compound six unapproved peptides while a formal decision is still pending [1].

Case for patient autonomy

• Right to try: patients whose needs current treatments don't meet may prefer to accept risk rather than wait years for trials to finish.
• Harm reduction: people already buy these products. Moving supply to licensed pharmacies [1] protects buyers from fakes. WHO estimates that 1 in 10 medical products in low- and middle-income countries is substandard or falsified [2].
• Dignity: blanket bans treat adults as unable to weigh risks for themselves, which is paternalistic.

Case for public-health safeguards

• Efficacy gap: a licensed pharmacy can check that a product is pure, but only clinical trials show that it works.
• Informed consent: without trial data, a patient's choice is not truly informed, so it is not fully autonomous.
• Legitimacy signal: access backed by the state draws healthy people into "wellness" and anti-ageing use.
• Systemic cost: countries spend about US$30.5 billion a year on substandard and falsified products [3]. Incidents reported to WHO's surveillance system rose nearly 60% in two years [4].
• Erosion of evidence norms: a temporary decision not to enforce can quietly become de facto approval.

Indian context and way forward

• India's national drug survey found 3.16% of 47,954 samples not of standard quality [5]. Wellness peptides sold online fall outside surveys like this.
• The draft e-pharmacy rules (2018) are still not final [6]. The Drugs, Medical Devices and Cosmetics Bill, 2022 would let the government set conditions for selling drugs online [7].
• Reforms: grant access only on conditions and for a fixed period, with patient registries and pharmacovigilance (tracking side effects); require a prescription for wellness injectables; test samples bought online.

Autonomy and safety do not have to conflict, because real choice depends on reliable evidence. Regulators should widen access through transparent channels that generate evidence, not through non-enforcement. That approach protects the right to health under Article 21 and the aim of SDG 3.8: safe, effective and affordable medicines for all.